REGAIN CONTROL OVER ADDICTION

Introducing the first prescription digital therapeutic for the treatment of patients with substance use disorder (SUD)

reSETTM for Substance Use Disorder

Pear Therapeutics has developed reSET®, a prescription digital therapeutic to be used in conjunction with standard outpatient treatment for substance use disorder (SUD)

reset-iphone

Patient-Facing Smartphone Application

reset-dashboard

Clinician-Facing Web Interface

reSETTM as a Prescription Digital Therapeutic for Treating Substance Use Disorder

reSET® has been proven to increase abstinence from a patient’s substances of abuse during treatment and increase patient retention in treatment when used as part of an outpatient treatment program

  • reSET® was evaluated in a clinical trial of 507 patients with SUD across 10 treatment centers nation-wide over 12 weeks.*
  • Patients were randomized to either a standard treatment as usual (TAU), which consisted of intensive face-to-face counseling, or to a reduced amount of face-to-face counseling plus reSET®.*

ABSTINENCE

  • Abstinence was measured twice weekly via urine analysis, breathalyzer, and self-reports.
  • In patients who were dependent on stimulants, marijuana, cocaine, or alcohol (n=395), 58.1% of patients receiving reSET®* were abstinent in study weeks 9-12, while 29.8% of patients receiving face-to-face therapy alone were abstinent during the same time frame (p<0.01).
  • Participants who tested positive for drug use at the start of the study (n=191), 26.7% of patients receiving reSET®* were abstinent in study weeks 9-12, while 3.2% of patients receiving traditional face-to-face therapy were abstinent during the same time frame (p<0.01).

All Patients

All Patients Retention final

Patients Non-Abstinent at Baseline

Patients Non-Abstinent at Baseline

RETENTION

  • Patients receiving reSET® showed statistically significant improvement in retention compared to face-to-face therapy alone (p=0.0316). At the end of 12 weeks of treatment 59% of patients receiving face-to-face therapy were retained in the study compared to 67% of patients receiving reSET®.

ENGAGEMENT

  • User engagement was measured in the pivotal study by comparing the average number of reSET® modules completed each week between patients abstinent and non-abstinent throughout the 12-week study.
  • Results show how all patients remain engaged throughout the study, and interestingly, the patients that were abstinent completed more modules per week.

Modules Completed per Week

graph-2-8

Time Spent on Modules

graph-3-8

1. Campbell et al. Am J Psychiatry. 2014.
2. Hubbard et al. Psychol Addict Behav. 1997.
3. Simpson. Am J Psychiatry. 1979.
4. Zhang et al. Addiction. 2003.
ClinicalTrials.gov Identifier: NCT01104805

For more information, please contact us

reSETTM is not yet available in the United States

* Therapeutic Education System (TES), which has equivalent content to reSET®, was tested. Please see labeling for study details.